Post by syedsanaullah on Jan 31, 2013 14:52:23 GMT -5
KPE Newsline Vol. 32 : Strategic Management
The world pharmaceutical industry has been changing profoundly in the last decade. Intensive globalization, increased competitiveness and the fight for global market shares create new challenges for pharmaceutical companies. Fast globalization definitively reinforces the consolidation of the world pharmaceutical industry. Alliancing in forms of mergers and acquisitions prevail more and more as a strategic orientation for the world pharmaceutical companies. By alliancing, they tend to create strategic synergies in an endeavour to be successful, competitive and capable to continue with further development circles. The mid level / SME pharmaceutical industry has been, to a great majority, taken- over by their multi-national peer companies, thus creating completely new managerial challenges. One may forecast that intensive alliancing processes in the world pharmaceutical industry are to continue to form even bigger pharmaceutical concerns and speed up the oligopolization of the global pharmaceutical industry. It can be concluded that strategic management with a dedicated market focus is to play an even more important and especially the highest top priority function in future globalization and consolidation processes of the world pharmaceutical industry.
Reasons of increased demand of strategic management professionals
• Changing structure of competition and increased competitiveness,
• Lack of new products, despite increased investments into R&D (Research & Development) activities,
• Fast consolidation and concentration of the world pharmaceutical industry,
• Increased development of new therapeutic fields and technologies (biotechnology, pharmacogenomics),
• Ageing of world population and opening up of new, not yet satisfactorily covered therapeutic fields,
• Quick development of the world generic markets.
This is why we emphasize that advanced strategic management course with a strong market orientation focus should be the most important strategic priority of a company that wants to be a successful business performer, to maintain its long-term sustainable growth, competitiveness and assure its long-term development and competitive market position.
In recent time more and more companies adopted for the inhouse-strategic management cell to carry out exclusive growth driver projects in the organization.
In KPE Strategic Management Course : Key Glimpses
New Drug Development Strategies, Lifecycle Management Strategies (Portfolio Management), Generic Drug Development and Management Strategies, Blockbuster Drug Management Strategies, Clinical Trial Management, Licensing for Growth – In Licensing Vs. Out Licensing, Co-marketing, Co-promotion, Reverse Co-promotion, Finance and Budget Planning, Merger, Acquisition, Drug Registration for International Marketing, Drug Dossier Preparation – CTD, ECTD, Drug Registration in different countries, Project Management Skill Development, Pharmaceutical Business Model Creation for Pharmaceutical Companies, Web and digital marketing strategy etc.
110 Lectures / Classes from different practical topics
300 Real Life Case Study specifically form Pharmaceutical Industry
Self Assessment Tests
Printed/Printable Modules
Download application form
Download Course Application form
Knowledge Area of strategic Management Professionals -
Vaccine market in India - A Growth Paotential
Asia is emerging as the vaccine hub of the world and India is on the go to play a key role in the vaccine market. The Global vaccine market is expected to reach $10 billion during the current year 2011. This is forecasted to scale up to $23.8 Billion by the year 2012 and to reach $40 billion by the year 2015. A sharp increase in sales is expected in areas of Influenza and Hepatitis vaccines. The v
Zydus Cadila has acquired 100% stake in Biochem
Zydus Cadila has acquired 100% stake in BiochemAhmedabad-based pharma major, Zydus Cadila, has acquired 100 per cent stake in Biochem, a Mumbai-based mid-sized drug company. Biochem has presence in therapeutic areas of antibiotics, cardiovascular, anti-diabetic and oncological segments. Financial details of the deal were not disclosed.Biochem had reported sales of Rs 264.5 crore for 2010-2011.Esta
Amgen - Focus, Planning and Future
With Amgen's recent decisions to acquire emerging market generic drug companies, partner with Watson for biosimilars development, and out-license non-core drugs to AstraZeneca, there's really no more dispute that Amgen has graduated to the ranks of Big Pharma. A Respectable Quarter Amgen delivered 9% revenue growth - just enough to edge out ahead of the average Wall Street guess. Growth was help
Revival of Wockhardt
Habil Khorakiwala, 70, chairman of generic drugmaker Wockhardt, says that the company's near-death experience has taught him lessons that he hopes will last generations. "We have decided not to touch derivative instruments. Some bankers still come to us with such products. I tell them, I don't want to risk my organisation in my lifetime or in my children's lifetime," says the septuagenarian chai
GlaxoSmithKline Plc and Biological Ejoint venture for the early-stage research and development of a six-in-one combination paediatric vaccine
GlaxoSmithKline Plc and Biological E Ltd said on Monday that they have signed an agreement to form an equal joint venture for the early-stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other infectious diseases.The partnership is also part of these companies’ commitment to support the Worl
Sun Pharma to acquire US-based DUSA for $230 mn
Sun Pharmaceutical Industries Thursday said it has inked a pact to acquire US-based DUSA Pharmaceuticals for around USD 230 million (around Rs 1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photodynamic therapy platform, Sun Pharma said in a s
Cipla to buy Cipla Medpro to consolidate international business
Cipla, India's second-largest drug firm, has agreed to acquire South Africandrugmaker Cipla Medpro, taking an important step towards consolidating its international business that now makes up more than half its quarterly revenues.Cipla said on Wednesday it will buy 51% of Cipla Medprofor about $220 million, valuing the beleaguered South African company at about $440 million. This is Cipla's first
Biocon and CCM deal: exclusive licence and distribution rights for its insulin products in Malyasia and Brune
Bangalore-based biotechnology firmBioconhas given CCM Pharmaceuticals, a subsidiary of Chemical Company of Malaysia, exclusive licence and distribution rights for its insulin products in Malyasiaand Brunei."The collaboration was in line with CCM's vision to pursue strategic partnerships to strengthen its pharmaceutical division's equity and portfolio in niche therapeutic areas such as oncology, bi
Piramal's entry in healthcare analytics and consulting business with acquisition of Decision Resources Group
The Ajay Piramal-led Piramal Healthcare Ltd has agreed to acquire US-based health information company Decision Resources Group (DRG) for $635 million (Rs. 3,400 crore), marking its entry into the $5.7 billion global healthcare database and consulting services industry. The acquisition is the third big investment by Piramal Healthcare in a year as it tries to diversify its business, using the c
AstraZeneca completes acquisition of California-based, Ardea Biosciences
AstraZeneca has completed acquisition of biotechnology company Ardea Biosciences, Inc. The merger was approved by Ardea’s stockholders. Upon completion of the merger, each outstanding share of Ardea common stock was cancelled and converted into the right to receive $32.00, in cash, without interest, and shares of Ardea common stock ceased trading on the Nasdaq Global Select Market. Earlier, the
Pharmaceutical Strategic Alliances - Growth Driver of Pharmaceutical Industry
The world pharmaceutical industry has been in the intensive processes of concentration and consolidation for a period of more than 15 years. As we argue that research and development and marketing and sales activities are two of the most important and strategic priorities of modern pharmaceutical companies and into which the greatest part of funds are being invested as well, we may say that the ma
Recently updated articles on Knowledge Base:
What is marketing campaign?
FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC
Novartis campaign to eliminate leprosy worldwide
FDA approves three new drug treatments for type 2 diabetes
U. S. Food and Drug Administration approved Bevacizumab
What is Botox?
FDA approves Botox to treat overactive bladder
FDA approves over-the-counter Oxytrol for Women to treat overactive bladder
FDA approves Exjade to remove excess iron in patients with genetic blood disorder
FDA approves Gleevec for children with acute lymphoblastic leukemia
Case Study - Development and approval guideline of biosimilar drug in Korea
GlaxoSmithKline Plc and Biological Ejoint venture for the early-stage research and development of a six-in-one combination paediatric vaccine
FDA regulations regarding drug labelling
Labeling changes for Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate)
Uniform codes of Pharmaceutical Marketing Practices
About NCK Pharma Solution Private Limited and our courses:
NCK Pharma Solution Private Limited has created a iconic training brand "Knowledge Proess Enhancer®" which is approved by International Assocoation of Distance Learning (IADL) registered under the Trademark Registry of India under section 42. KPE is conceptualized with a vision to spearhead innovation in the field of Pharmaceutical, Biotechnology, Medical Devices learinng with the technological advances. The mission is to provide "Best On the go" training services across those industries to create, develop, train tomorrows leaders. All courses are designed by the industry mentors keeping industry working in mind.
KPE courses are designed for working in industry. All courses are covered with the recent insights and detailed understanding with audio visual lectures, animated self assessment modules with dynamic up todate study material.
Features of our courses:
1. You can attend lectures, online sessions, discussion and case study from your computer at your convenient timing with your personalized webpage.
2. Access to Pharma Forums, Knowledge Base, Pharma Dictionary and many more attractive applications.
3. Final Examination is online with 'SECURE EXAM' technology, you can access from anywhere, anytime.
4. Our courses are recognized globally - approved by International Association of Distance Learning, UK.
4. Case studies -for orientation.
5. 24x7 Mentor support / doubt clearing support.
6. Access to Pharma Forum, Knowledge Base and many more attractive applications to enhance the skill.
Open source Pharma Resources:
Explore the KPE Pharma Knowledge Base - 1000s of articles and case studies
Pharma Dictinary: Open source Pharma Dictionary
KPE Course Admission is now open for Feb Batch, 2012.
Download application form
Download Course Application form
----------------------------------------------------------------------------------------
KPE Courses List
1. KPE Advance Diploma - 1 Year Program
• Drug Regulatory Affairs
• Pharmaceutical Product Management
• Pharmaceutical Sales Management
• Pharmaceutical Marketing Management
• Pharmaceutical Production Management
• Herbal & Ayurvedic Product Management
• Pharmaceutical Strategic Management
2. KPE 1 Month Certificate Pogram
• The Drug Development Process Discovery to Commercialization
• GMP and GMP Audit
• Drug Registration in ASEAN countries
• Drug Registration and Dossier Preparation
• Intellectual Property Management in Pharmaceuticals
• Practical Training on Pharmaceutical Promotion Management
• Concept of Generic Drug and Approval Process
• Quality Assurance and Documentation
• Medical Device Regulation
• Licensing in Pharmaceutical
• API - Regulatory Affairs
• European Drug Regulatory Affairs
3. KPE 1 Week / 7 Days Certificate Training
• Medical Representatives Certification Training
• Sales Forecasting and Analysis for Pharma Managers
• Preparing Batch Manufacturing Records for Pharmaceuticals
• Innovation Management in Pharmaceutical Management
• Para IV Filing
• Regulatory Strategies for Pharmaceutical companies
• Portfolio Management for Pharmaceutical Companies
• Pharmaceutical Packaging - Importance, Design and Regulatory perspective
• OTC Drugs Marketing Strategies
4. KPE 3 Days Orientation Program
• Product Lifecycle Management in Pharmaceuticals
• Drug Registration Process in India
• New Product Launch strategies for pharmaceuticals
• Finance skills for pharmaceutical managers
• Orientation to Drug Regulatory Affairs
• Product Manager Skill Development Program
The world pharmaceutical industry has been changing profoundly in the last decade. Intensive globalization, increased competitiveness and the fight for global market shares create new challenges for pharmaceutical companies. Fast globalization definitively reinforces the consolidation of the world pharmaceutical industry. Alliancing in forms of mergers and acquisitions prevail more and more as a strategic orientation for the world pharmaceutical companies. By alliancing, they tend to create strategic synergies in an endeavour to be successful, competitive and capable to continue with further development circles. The mid level / SME pharmaceutical industry has been, to a great majority, taken- over by their multi-national peer companies, thus creating completely new managerial challenges. One may forecast that intensive alliancing processes in the world pharmaceutical industry are to continue to form even bigger pharmaceutical concerns and speed up the oligopolization of the global pharmaceutical industry. It can be concluded that strategic management with a dedicated market focus is to play an even more important and especially the highest top priority function in future globalization and consolidation processes of the world pharmaceutical industry.
Reasons of increased demand of strategic management professionals
• Changing structure of competition and increased competitiveness,
• Lack of new products, despite increased investments into R&D (Research & Development) activities,
• Fast consolidation and concentration of the world pharmaceutical industry,
• Increased development of new therapeutic fields and technologies (biotechnology, pharmacogenomics),
• Ageing of world population and opening up of new, not yet satisfactorily covered therapeutic fields,
• Quick development of the world generic markets.
This is why we emphasize that advanced strategic management course with a strong market orientation focus should be the most important strategic priority of a company that wants to be a successful business performer, to maintain its long-term sustainable growth, competitiveness and assure its long-term development and competitive market position.
In recent time more and more companies adopted for the inhouse-strategic management cell to carry out exclusive growth driver projects in the organization.
In KPE Strategic Management Course : Key Glimpses
New Drug Development Strategies, Lifecycle Management Strategies (Portfolio Management), Generic Drug Development and Management Strategies, Blockbuster Drug Management Strategies, Clinical Trial Management, Licensing for Growth – In Licensing Vs. Out Licensing, Co-marketing, Co-promotion, Reverse Co-promotion, Finance and Budget Planning, Merger, Acquisition, Drug Registration for International Marketing, Drug Dossier Preparation – CTD, ECTD, Drug Registration in different countries, Project Management Skill Development, Pharmaceutical Business Model Creation for Pharmaceutical Companies, Web and digital marketing strategy etc.
110 Lectures / Classes from different practical topics
300 Real Life Case Study specifically form Pharmaceutical Industry
Self Assessment Tests
Printed/Printable Modules
Download application form
Download Course Application form
Knowledge Area of strategic Management Professionals -
Vaccine market in India - A Growth Paotential
Asia is emerging as the vaccine hub of the world and India is on the go to play a key role in the vaccine market. The Global vaccine market is expected to reach $10 billion during the current year 2011. This is forecasted to scale up to $23.8 Billion by the year 2012 and to reach $40 billion by the year 2015. A sharp increase in sales is expected in areas of Influenza and Hepatitis vaccines. The v
Zydus Cadila has acquired 100% stake in Biochem
Zydus Cadila has acquired 100% stake in BiochemAhmedabad-based pharma major, Zydus Cadila, has acquired 100 per cent stake in Biochem, a Mumbai-based mid-sized drug company. Biochem has presence in therapeutic areas of antibiotics, cardiovascular, anti-diabetic and oncological segments. Financial details of the deal were not disclosed.Biochem had reported sales of Rs 264.5 crore for 2010-2011.Esta
Amgen - Focus, Planning and Future
With Amgen's recent decisions to acquire emerging market generic drug companies, partner with Watson for biosimilars development, and out-license non-core drugs to AstraZeneca, there's really no more dispute that Amgen has graduated to the ranks of Big Pharma. A Respectable Quarter Amgen delivered 9% revenue growth - just enough to edge out ahead of the average Wall Street guess. Growth was help
Revival of Wockhardt
Habil Khorakiwala, 70, chairman of generic drugmaker Wockhardt, says that the company's near-death experience has taught him lessons that he hopes will last generations. "We have decided not to touch derivative instruments. Some bankers still come to us with such products. I tell them, I don't want to risk my organisation in my lifetime or in my children's lifetime," says the septuagenarian chai
GlaxoSmithKline Plc and Biological Ejoint venture for the early-stage research and development of a six-in-one combination paediatric vaccine
GlaxoSmithKline Plc and Biological E Ltd said on Monday that they have signed an agreement to form an equal joint venture for the early-stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other infectious diseases.The partnership is also part of these companies’ commitment to support the Worl
Sun Pharma to acquire US-based DUSA for $230 mn
Sun Pharmaceutical Industries Thursday said it has inked a pact to acquire US-based DUSA Pharmaceuticals for around USD 230 million (around Rs 1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photodynamic therapy platform, Sun Pharma said in a s
Cipla to buy Cipla Medpro to consolidate international business
Cipla, India's second-largest drug firm, has agreed to acquire South Africandrugmaker Cipla Medpro, taking an important step towards consolidating its international business that now makes up more than half its quarterly revenues.Cipla said on Wednesday it will buy 51% of Cipla Medprofor about $220 million, valuing the beleaguered South African company at about $440 million. This is Cipla's first
Biocon and CCM deal: exclusive licence and distribution rights for its insulin products in Malyasia and Brune
Bangalore-based biotechnology firmBioconhas given CCM Pharmaceuticals, a subsidiary of Chemical Company of Malaysia, exclusive licence and distribution rights for its insulin products in Malyasiaand Brunei."The collaboration was in line with CCM's vision to pursue strategic partnerships to strengthen its pharmaceutical division's equity and portfolio in niche therapeutic areas such as oncology, bi
Piramal's entry in healthcare analytics and consulting business with acquisition of Decision Resources Group
The Ajay Piramal-led Piramal Healthcare Ltd has agreed to acquire US-based health information company Decision Resources Group (DRG) for $635 million (Rs. 3,400 crore), marking its entry into the $5.7 billion global healthcare database and consulting services industry. The acquisition is the third big investment by Piramal Healthcare in a year as it tries to diversify its business, using the c
AstraZeneca completes acquisition of California-based, Ardea Biosciences
AstraZeneca has completed acquisition of biotechnology company Ardea Biosciences, Inc. The merger was approved by Ardea’s stockholders. Upon completion of the merger, each outstanding share of Ardea common stock was cancelled and converted into the right to receive $32.00, in cash, without interest, and shares of Ardea common stock ceased trading on the Nasdaq Global Select Market. Earlier, the
Pharmaceutical Strategic Alliances - Growth Driver of Pharmaceutical Industry
The world pharmaceutical industry has been in the intensive processes of concentration and consolidation for a period of more than 15 years. As we argue that research and development and marketing and sales activities are two of the most important and strategic priorities of modern pharmaceutical companies and into which the greatest part of funds are being invested as well, we may say that the ma
Recently updated articles on Knowledge Base:
What is marketing campaign?
FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC
Novartis campaign to eliminate leprosy worldwide
FDA approves three new drug treatments for type 2 diabetes
U. S. Food and Drug Administration approved Bevacizumab
What is Botox?
FDA approves Botox to treat overactive bladder
FDA approves over-the-counter Oxytrol for Women to treat overactive bladder
FDA approves Exjade to remove excess iron in patients with genetic blood disorder
FDA approves Gleevec for children with acute lymphoblastic leukemia
Case Study - Development and approval guideline of biosimilar drug in Korea
GlaxoSmithKline Plc and Biological Ejoint venture for the early-stage research and development of a six-in-one combination paediatric vaccine
FDA regulations regarding drug labelling
Labeling changes for Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate)
Uniform codes of Pharmaceutical Marketing Practices
About NCK Pharma Solution Private Limited and our courses:
NCK Pharma Solution Private Limited has created a iconic training brand "Knowledge Proess Enhancer®" which is approved by International Assocoation of Distance Learning (IADL) registered under the Trademark Registry of India under section 42. KPE is conceptualized with a vision to spearhead innovation in the field of Pharmaceutical, Biotechnology, Medical Devices learinng with the technological advances. The mission is to provide "Best On the go" training services across those industries to create, develop, train tomorrows leaders. All courses are designed by the industry mentors keeping industry working in mind.
KPE courses are designed for working in industry. All courses are covered with the recent insights and detailed understanding with audio visual lectures, animated self assessment modules with dynamic up todate study material.
Features of our courses:
1. You can attend lectures, online sessions, discussion and case study from your computer at your convenient timing with your personalized webpage.
2. Access to Pharma Forums, Knowledge Base, Pharma Dictionary and many more attractive applications.
3. Final Examination is online with 'SECURE EXAM' technology, you can access from anywhere, anytime.
4. Our courses are recognized globally - approved by International Association of Distance Learning, UK.
4. Case studies -for orientation.
5. 24x7 Mentor support / doubt clearing support.
6. Access to Pharma Forum, Knowledge Base and many more attractive applications to enhance the skill.
Open source Pharma Resources:
Explore the KPE Pharma Knowledge Base - 1000s of articles and case studies
Pharma Dictinary: Open source Pharma Dictionary
KPE Course Admission is now open for Feb Batch, 2012.
Download application form
Download Course Application form
----------------------------------------------------------------------------------------
KPE Courses List
1. KPE Advance Diploma - 1 Year Program
• Drug Regulatory Affairs
• Pharmaceutical Product Management
• Pharmaceutical Sales Management
• Pharmaceutical Marketing Management
• Pharmaceutical Production Management
• Herbal & Ayurvedic Product Management
• Pharmaceutical Strategic Management
2. KPE 1 Month Certificate Pogram
• The Drug Development Process Discovery to Commercialization
• GMP and GMP Audit
• Drug Registration in ASEAN countries
• Drug Registration and Dossier Preparation
• Intellectual Property Management in Pharmaceuticals
• Practical Training on Pharmaceutical Promotion Management
• Concept of Generic Drug and Approval Process
• Quality Assurance and Documentation
• Medical Device Regulation
• Licensing in Pharmaceutical
• API - Regulatory Affairs
• European Drug Regulatory Affairs
3. KPE 1 Week / 7 Days Certificate Training
• Medical Representatives Certification Training
• Sales Forecasting and Analysis for Pharma Managers
• Preparing Batch Manufacturing Records for Pharmaceuticals
• Innovation Management in Pharmaceutical Management
• Para IV Filing
• Regulatory Strategies for Pharmaceutical companies
• Portfolio Management for Pharmaceutical Companies
• Pharmaceutical Packaging - Importance, Design and Regulatory perspective
• OTC Drugs Marketing Strategies
4. KPE 3 Days Orientation Program
• Product Lifecycle Management in Pharmaceuticals
• Drug Registration Process in India
• New Product Launch strategies for pharmaceuticals
• Finance skills for pharmaceutical managers
• Orientation to Drug Regulatory Affairs
• Product Manager Skill Development Program